Radiotherapy alone vs combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: A Phase III randomized clinical trial INOPERABL KUCUK HUCRELI DISI AKCIGER KANSERINDE HIPERFRAKSIYONE RADYOTERAPI ILE CISPLATIN + 5FU KOMBINASYONUNUN YERI: RANDOMIZE PROSPEKTIF KLINIK CALISMA
Cerrahpasa Tip Dergisi, cilt.27, sa.2, ss.63-69, 1996 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 27 Sayı: 2
- Basım Tarihi: 1996
- Dergi Adı: Cerrahpasa Tip Dergisi
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.63-69
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır
Özet
Background and Design. - Treatment of regionally advanced non-small cell lung cancer (NSCLC) is unsatisfactory. Combined irradiation with chemotherapy may improve local control rates and systemic disease. This study was designed to test the efficacy of radiotherapy alone versus combined chemotherapy (cisplatinum, 5-FU, etoposide). Thirty-four patients with NSCLC were randomly allocated to A) Conventional radiotherapy, B) hyperfractionated radiotherapy, C) conventional radiotherapy plus chemotherapy, D) hyperfractionated radiotherapy plus chemotherapy groups. Results. - Local control rates (60-71 %) and overall survival rates were not different in between groups. Toxic side effects were common in groups c and d in which there were 2 drop-outs and 3 patients with grade III-IV toxicity. All patients died within 2 years. Conclusion. - No beneficial effect was obtained by chemo- and radiotherapy combination protocol in NSCLC, and it was associated with high and severe toxic side effects.